These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

961 related items for PubMed ID: 20848380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 3. Access to orphan drugs in Europe: current and future issues.
    Michel M, Toumi M.
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [Abstract] [Full Text] [Related]

  • 4. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.
    Ned Tijdschr Geneeskd; 2012 Feb; 156(17):A4252. PubMed ID: 22531041
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 8. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
    Janzen RW, Ludwig WD, Arzneimittelkommission der deutschen Ärzteschaft, Berlin.
    Z Rheumatol; 2012 Feb 05; 71(2):108-10, 112-8. PubMed ID: 22370801
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul 05; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [European incentives for orphan medicinal products].
    Enzmann H, Lütz J.
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May 19; 51(5):500-8. PubMed ID: 18696141
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S.
    J Pharm Belg; 2009 Dec 19; (4):131-7. PubMed ID: 20183989
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.